Mineralys Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024

TL;DR

<b>Mineralys Therapeutics, Inc. has filed its quarterly report (10-Q) for the period ending March 31, 2024, detailing its financial and operational status.</b>

AI Summary

Mineralys Therapeutics, Inc. (MLYS) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Mineralys Therapeutics, Inc. filed a 10-Q report for the quarterly period ended March 31, 2024. The company's principal business address is located at 150 N. Radnor Chester Road, Suite F200, Radnor, PA 19087. The filing covers the period from January 1, 2024, to March 31, 2024. Key dates include the IPO on February 14, 2023. The company is incorporated in Delaware and operates in the Pharmaceutical Preparations industry (SIC 2834).

Why It Matters

For investors and stakeholders tracking Mineralys Therapeutics, Inc., this filing contains several important signals. This 10-Q filing provides investors and stakeholders with the latest financial performance and operational updates for Mineralys Therapeutics, Inc. during the first quarter of 2024. Understanding the details within this report is crucial for assessing the company's current financial health, strategic direction, and potential future performance in the pharmaceutical sector.

Risk Assessment

Risk Level: low — Mineralys Therapeutics, Inc. shows low risk based on this filing. The risk is low as this is a standard quarterly filing (10-Q) providing routine financial and operational information, with no immediate red flags or significant negative developments indicated in the header data.

Analyst Insight

Review the detailed financial statements and management's discussion and analysis within the 10-Q to understand the company's performance and outlook.

Key Numbers

• 2024-03-31 — Period End Date (Conformed period of report)
• 2024-05-09 — Filing Date (Filed as of date)
• 2023-02-14 — IPO Date (US GAAP IPO Member)

Key Players & Entities

• Mineralys Therapeutics, Inc. (company) — Filer name
• 2024-03-31 (date) — Conformed period of report
• 2024-05-09 (date) — Filed as of date
• 150 N. RADNOR CHESTER ROAD (address) — Business address street 1
• RADNOR (location) — Business address city
• PA (location) — Business address state
• 19087 (postal_code) — Business address zip
• 2834 (industry_code) — Standard Industrial Classification

FAQ

Industry Context

Mineralys Therapeutics operates within the Pharmaceutical Preparations industry, focusing on the development and commercialization of pharmaceutical products.

Regulatory Implications

As a public company, Mineralys Therapeutics is subject to the reporting requirements of the Securities and Exchange Commission (SEC), including the filing of quarterly reports on Form 10-Q.

What Investors Should Do

1. Analyze the financial statements for revenue, expenses, and cash flow.
2. Review the Management's Discussion and Analysis of Financial Condition and Results of Operations for insights into performance drivers.
3. Examine any disclosed risk factors or legal proceedings.

Key Dates

• 2024-03-31: Quarterly Period End — End of the reporting period for the 10-Q filing.
• 2024-05-09: Filing Date — Date the 10-Q report was officially filed with the SEC.
• 2023-02-14: IPO Date — Significant past event related to the company's public offering.

Year-Over-Year Comparison

This is the first 10-Q filing for the fiscal year 2024, following the 10-K filed for the fiscal year ended December 31, 2023.

Key Financial Figures

• $0.0001 — nge on which registered Common stock, $0.0001 par value per share MLYS The Nasdaq S

Filing Documents

• mlys-20240331.htm (10-Q) — 602KB
• mlys-1q2410qex311.htm (EX-31.1) — 10KB
• mlys-1q2410qex312.htm (EX-31.2) — 10KB
• mlys-1q2410qex321.htm (EX-32.1) — 5KB
• mlys-1q2410qex322.htm (EX-32.2) — 5KB
• 0001933414-24-000016.txt (&nbsp;) — 3519KB
• mlys-20240331.xsd (EX-101.SCH) — 28KB
• mlys-20240331_cal.xml (EX-101.CAL) — 34KB
• mlys-20240331_def.xml (EX-101.DEF) — 113KB
• mlys-20240331_lab.xml (EX-101.LAB) — 371KB
• mlys-20240331_pre.xml (EX-101.PRE) — 258KB
• mlys-20240331_htm.xml (XML) — 317KB

- Financial Information

Part I - Financial Information 1

Financial Statements

Item 1. Financial Statements 1

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 15

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 27

Controls and Procedures

Item 4. Controls and Procedures 27

- Other Information

Part II - Other Information 29

Legal Proceedings

Item 1. Legal Proceedings 29

Risk Factors

Item 1A. Risk Factors 29

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 29

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 29

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 29

Other Information

Item 5. Other Information 29

Exhibits

Item 6. Exhibits 29 i Table of Contents

- Financial Information

Part I - Financial Information

Financial Statements

Item 1. Financial Statements Mineralys Therapeutics, Inc. Condensed Balance Sheets (in thousands, except share and per share amounts) March 31, December 31, 2024 2023 (unaudited) Assets Current assets: Cash and cash equivalents $ 90,418 $ 49,304 Investments 248,147 187,263 Prepaid and other current assets 8,254 12,536 Total current assets 346,819 249,103 Investments, noncurrent — 2,482 Property and equipment, net 51 — Other assets 379 51 Total assets $ 347,249 $ 251,636 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 4,261 $ 601 Accrued liabilities 14,943 9,881 Total current liabilities 19,204 10,482 Commitments and contingencies (Note 4) Stockholders' equity: Common stock, $ 0.0001 par value; 500,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 49,632,989 and 41,133,916 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively 5 4 Additional paid-in capital 484,256 365,858 Accumulated deficit ( 156,216 ) ( 124,708 ) Total stockholders' equity 328,045 241,154 Total liabilities and stockholders' equity $ 347,249 $ 251,636 The accompanying notes are an integral part of these condensed financial statements. 1 Table of Contents Mineralys Therapeutics, Inc. Condensed Statements of Operations (in thousands, except share and per share data) (unaudited) Three Months Ended March 31, 2024 2023 Operating expenses: Research and development $ 30,754 $ 12,293 General and administrative 4,608 2,645 Total operating expenses 35,362 14,938 Loss from operations ( 35,362 ) ( 14,938 ) Interest income, net 3,853 2,329 Other income 1 1 Total other income, net 3,854 2,330 Net loss $ ( 31,508 ) $ ( 12,608 ) Net loss per share attributable to common stockholders, basic and diluted $ ( 0.70 ) $ ( 0.51 ) Weighted-average shares used to compute net loss per share attributable to common stockholders, basic and diluted 44,900,755 24,764,469 The accompanying

View Full Filing

View this 10-Q filing on SEC EDGAR